Biorasi, Cardium sales and marketing update

Cardium granted bioRASI's Advanced Biosciences Research affiliate rights to commercialize wound care product Excellagen in the Commonwealth of Independent States (CIS). bioRASI is responsible for regulatory approval and will co-develop a marketing, sales and distribution infrastructure plan in the territories following Excellagen's approval. Details were not disclosed. FDA approved the topical collagen-based gel matrix to manage diabetic foot ulcers and other dermal wounds last year (see BioCentury, Oct. 17, 2011). ...